Supplement | HBS Case Collection | January 2014

Amgen Inc.: Pursuing Innovation and Imitation? (B)

by Ian MacKenzie

Abstract

The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The (B) case then focuses on how the new business should be implemented, particularly in terms of integration versus separation of a new business unit, choice of unit leader, and whether Amgen should partner with a third party to gain access to skills or resources.

Keywords: corporate strategy; pharmaceutical industry; Biotechnology Industry; Corporate Strategy; Pharmaceutical Industry; Biotechnology Industry; United States;

Citation:

MacKenzie, Ian. "Amgen Inc.: Pursuing Innovation and Imitation? (B)." Harvard Business School Supplement 714-426, January 2014.